SOUTH SAN FRANCISCO, Calif. / Mar 11, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time.
“At Twist, we recognize the increasing challenge within colleges, universities and research institutions to securing research funding and appreciate that scientific progress must continue unhindered, as Science Doesn’t Stop,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We constantly look for ways to meet the academic research community in their place of need. By making Express shipping the default option at no additional cost, we reinforce our commitment to advancing science while supporting researchers as they navigate constrained budgets.”
Twist Express Genes
Twist Express Genes are 0.3kb to 5.0kb in length. Due to the scale of synthesis enabled by Twist's platform, any order volume can be fulfilled, from small to large. As with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified and one hundred percent accurate. Twist Express Genes can be cloned into catalog vectors or custom vectors so that customers can move right to experimentation. They can also be shipped in customers’ preferred delivery formats, including tubes and plates. For more information and product specifications click here. To begin order, click here.
*Turnaround time for Clonal Genes is subject to change based on customizations and complexity.
About Twist Bioscience
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram | Bluesky
Last Trade: | US$37.50 |
Daily Change: | -0.71 -1.86 |
Daily Volume: | 1,714,800 |
Market Cap: | US$2.230B |
March 31, 2025 February 03, 2025 November 18, 2024 November 14, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load